Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 17/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 15/20 | 0.41 |
| ▸ | CDK2 | P24941 | 15/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 15/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542647 | 0.93 | CHEK1 (0.41) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL10280551 | 0.91 | CHEK1 (0.39) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL10280630 | 0.91 | CHEK1 (0.39) | CHEK1CCNA2CDK2CCNA1SRC | |
| SCHEMBL13675254 | 0.91 | CHEK1 (0.39) | CHEK1CCNA2CDK2CCNA1SRC | |
| SCHEMBL10280158 | 0.91 | CHEK1 (0.39) | CHEK1CCNA2CDK2CCNA1SRC | |
| SCHEMBL14542662 | 0.91 | CHEK1 (0.39) | CHEK1CCNA2CDK2CCNA1SRC | |
| SCHEMBL11937072 | 0.88 | CHEK1 (0.38) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL13675271 | 0.88 | CHEK1 (0.38) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14542638 | 0.87 | CHEK1 (0.38) | CHEK1CCNA2CDK2CCNA1SRC | |
| SCHEMBL11936836 | 0.87 | CHEK1 (0.40) | CHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605155-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CHEK1 60/4885CCNA2 29/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.